This webinar will discuss the best practices for how molecular diagnostic labs can quickly and effectively launch next-generation sequencing (NGS) hereditary risk genetic testing. The webinar will explore how to implement an effective testing program, particularly market trends and considerations, laboratory setup and validation, data analysis, and reporting, and will share best practices for selecting and implementing a tertiary analysis pipeline for variant interpretation.
Clinical laboratories are rapidly expanding the scope and complexity of their hereditary testing services offered to utilize next-generation sequencing. With this expansion comes a significant number of challenges, including setup, panel design and validation, how to build for optimum turnaround time, and the need for specialized clinical genetic knowledge and overall scalability. A good strategy for selecting and implementing appropriate tertiary analysis tools and setting up a scalable interpretation workflow is critical to the success of a clinical NGS program.
Tootie Tatum is the Founder and CEO of Blackhawk Genomics. A clinical genomic scientist with over 20 years of experience in molecular diagnostics in academic medical centers and commercial laboratories, she is one of a few individuals worldwide to have developed project management and workflow systems for large genome sequencing centers. Dr. Tatum currently serves on the American Board of Bioanalysis and is a Next-Generation Sequencing (NGS) and Molecular Pathology Specialty Inspector for the College of American Pathologists (CAP). She is also the CLIA laboratory director for the UPMC Genome Center and the Discovery Life Sciences Clinical Genomics Laboratory.
Charlene Son Rigby is responsible for customer success, business development, and regulatory at Fabric Genomics. She has spent her career building businesses at the intersection of data, technology, and life sciences. Before joining Fabric Genomics, Son Rigby was responsible for all go-to-market activities at Metamarkets, a big data analytics startup, was Vice President of Business Planning at Oracle, and Executive Director of Sales Operations at Siebel Systems, a $2B license business. Son Rigby also led product management at DoubleTwist, a bioinformatics startup. She started her career as a neuroscience researcher at Syntex (acquired by Roche). Son Rigby holds a BA in Human Biology from Stanford University and an MBA from the Haas School of Business at U.C. Berkeley.
